

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>BAKER FELIX</u>  (Last) (First) (Middle) 667 MADISON AVENUE, 21ST FLOOR  (Street) NEW YORK NY US 10065  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>BIOCRYS T PHARMACEUTICALS INC [ BCRX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner  Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 08/01/2013	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock								17,241	I	See footnote <sup>(1)(7)(8)</sup>
Common Stock								34,046	I	See footnote <sup>(2)(7)(8)</sup>
Common Stock								28,361	I	See footnote <sup>(3)(7)(8)</sup>
Common Stock	08/01/2013		P		120,498	A	\$4.4	1,642,513	I	See footnote <sup>(4)(7)(8)</sup>
Common Stock	08/01/2013		P		991,161	A	\$4.4	4,832,285	I	See footnote <sup>(5)(7)(8)</sup>
Common Stock	08/01/2013		P		24,705	A	\$4.4	145,533	I	See footnote <sup>(6)(7)(8)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
BAKER FELIX  
 (Last) (First) (Middle)  
 667 MADISON AVENUE, 21ST FLOOR  
 (Street)  
 NEW YORK NY US 10065  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Baker Bros. Investments II, L.P.  
 (Last) (First) (Middle)  
 667 MADISON AVENUE 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Baker/Tisch Investments, LP](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[667, L.P.](#)

(Last) (First) (Middle)

667 MADISON AVENUE 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Baker Brothers Life Sciences LP](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[14159, L.P.](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[BAKER BROS. ADVISORS LP](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[BAKER JULIAN](#)

(Last) (First) (Middle)

667 MADISON AVENUE, 21ST FLOOR

(Street)  
NEW YORK NY US 10065

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Baker Bros. Advisors (GP) LLC</a>		
(Last)	(First)	(Middle)
667 MADISION AVENUE 21ST FLOOR		
(Street)		
NEW YORK	NY	US 10065
(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<a href="#">Baker Bros. Investments, L.P.</a>		
(Last)	(First)	(Middle)
667 MADISON AVENUE		
(Street)		
NEW YORK	NY	US 10065
(City)	(State)	(Zip)

**Explanation of Responses:**

- As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Tisch Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 17,241 shares of Common Stock of the Issuer beneficially owned by Baker Tisch Investments, L.P., a limited partnership of which the sole general partner is Baker Tisch Capital, L.P., a limited partnership of which the sole general partner is Baker Tisch Capital (GP), LLC, due to Baker Tisch Capital L.P.'s right to receive an allocation of a portion of the profits from Baker Tisch Investments, L.P.
- As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Bros. Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 34,046 shares of Common Stock of the Issuer beneficially owned by Baker Bros. Investments, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital (GP), LLC, due to Baker Bros. Capital, L.P.'s right to receive an allocation of a portion of the profits from Baker Bros. Investments, L.P.
- As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Bros. Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 28,361 shares of Common Stock of the Issuer beneficially owned by Baker Bros. Investments II, L.P., a limited partnership of which the sole general partner is Baker Bros. Capital (GP), LLC, due to Baker Bros. Capital, L.P.'s right to receive an allocation of a portion of the profits from Baker Bros. Investments II, L.P.
- As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Biotech Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 1,642,513 shares of Common Stock of the Issuer beneficially owned by 667, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667, L.P.
- As a result of Felix J. Baker's and Julian C. Baker's ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest 4,832,285 shares of Common Stock of the Issuer beneficially owned by Baker Brothers Life Sciences, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Baker Brothers Life Sciences, L.P.
- As a result of Felix J. Baker's and Julian C. Baker's ownership interest in 14159 Capital (GP), LLC, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in 145,533 shares of Common Stock of the Issuer beneficially owned by 14159, L.P., a limited partnership of which the sole general partner is 14159 Capital L.P., a limited partnership of which the sole general partner is 14159 Capital (GP), LLC, due to 14159 Capital L.P.'s right to receive an allocation of a portion of the profits from 14159, L.P.
- The aggregate indirect beneficial ownership reported on this form is 6,699,979 shares.
- Baker Bros. Advisors LP (the "Adviser") serves as the Investment Adviser to Baker Tisch Investments, L.P., Baker Bros. Investments, L.P., Baker Bros. Investments II, L.P., 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P. (the "Funds"). In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the Adviser GP) is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are principals of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

[/s/ Felix J. Baker](#) [08/02/2013](#)

[Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
BAKER BROS  
INVESTMENTS II, L.P.,  
pursuant to authority granted  
by Baker Bros. Capital, L.P.,  
GP to Baker Bros. Investments  
II, L.P Name:Scott L. Lessing,  
Title: President /s/ Scott L.  
Lessing](#) [08/02/2013](#)

[Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
BAKER TISCH  
INVESTMENTS, L.P.,  
pursuant to authority granted  
by Baker Tisch Capital, L.P.,  
GP to Baker Tisch Investment,  
L.P Name:Scott L. Lessing.  
Title: President /s/ Scott L.  
Lessing](#) [08/02/2013](#)

[Baker Bros. Advisors LP,  
Mgmt. Co. and Inv. Adviser to  
667, L.P., pursuant to authority  
granted by Baker Biotech  
Capital, L.P., GP to 667, L.P  
Name:Scott L. Lessing, Title:  
President /s/ Scott L. Lessing](#) [08/02/2013](#)

[Baker Bros. Advisors LP,](#) [08/02/2013](#)  
[Mgmt. Co. and Inv. Adviser to](#)  
[BAKER BROTHERS LIFE](#)  
[SCIENCES, L.P., pursuant to](#)  
[authority granted by Baker](#)  
[Brothers Life Sciences Capital,](#)  
[L.P., GP to Baker Brothers Life](#)  
[Sciences, L.P Name:Scott L.](#)  
[Lessing, Title: President /s/](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**